INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
INOVIO (NASDAQ: INO) reported its Q1 2024 financial results and recent business highlights. The company is on track to submit a BLA for INO-3107 in the second half of 2024, aiming to become the first non-surgical treatment for recurrent respiratory papillomatosis (RRP). A confirmatory trial for INO-3107 is planned, with FDA feedback incorporated. INOVIO also plans a Phase 3 trial of INO-3112 in combination with LOQTORZI for treating HPV-16/18 positive oropharyngeal squamous cell carcinoma (OPSCC).
Financially, INOVIO's cash, equivalents, and short-term investments stood at $105.6 million as of March 31, 2024, down from $145.3 million in December 2023. The company completed a $33.2 million stock and pre-funded warrants offering in April 2024, extending its cash runway to Q3 2025. Q1 R&D expenses decreased from $30.2 million in 2023 to $20.9 million, while G&A expenses dropped from $13.9 million to $10.6 million. The net loss improved to $30.5 million ($1.31 per share) from $40.6 million ($1.89 per share) in Q1 2023, following a reverse stock split in January 2024.
- On track for INO-3107 BLA submission in H2 2024, potentially the first non-surgical RRP treatment.
- Confirmatory trial for INO-3107 incorporating FDA feedback is planned.
- Plans for Phase 3 trial of INO-3112 with LOQTORZI for HPV-16/18 positive OPSCC.
- Balance sheet bolstered by a $33.2 million stock offering in April 2024.
- Cash runway projected into Q3 2025.
- R&D expenses decreased from $30.2 million to $20.9 million YoY.
- G&A expenses reduced from $13.9 million to $10.6 million YoY.
- Net loss decreased to $30.5 million from $40.6 million YoY.
- Cash, equivalents, and short-term investments fell from $145.3 million to $105.6 million.
- Continued operational net cash burn, estimated at $30 million for Q2 2024.
- Revenue and earnings figures are not highlighted, suggesting potential struggles in these areas.
Insights
The first quarter 2024 financial results reveal a mixed but generally positive outlook for INOVIO. Research and Development (R&D) expenses decreased by
Additionally, General and Administrative (G&A) expenses fell from
Cash and short-term investments dropped from
For retail investors, it is important to monitor INOVIO's cash burn rate and subsequent capital-raising activities, as these will impact the company's ability to sustain its operations and achieve its ambitious clinical trial plans.
The planned BLA submission for INO-3107 in the latter half of 2024 under the accelerated approval pathway could represent a transformative step for the company. If approved, INO-3107 would be the first non-surgical treatment for recurrent respiratory papillomatosis (RRP), a disease currently managed through frequent and risky surgical interventions. The clinical trial design for INO-3107 appears robust, focusing on real-world reductions in surgical necessity, a critical metric for both patients and healthcare providers.
The advancements in preparing for a Phase 3 trial of INO-3112 in combination with LOQTORZI for oropharyngeal squamous cell carcinoma (OPSCC) also stand out. This trial, which aligns with FDA feedback and aims to be conducted in both North America and Europe, underscores INOVIO's strategic efforts to address substantial unmet needs in high-risk HPV-related cancers. The potential combination therapy with LOQTORZI, a PD-1 inhibitor, could augment the immune response generated by INO-3112, potentially leading to better clinical outcomes.
For retail investors, the progression of these trials and subsequent FDA approvals could significantly enhance the company's valuation and market position. These developments should be closely monitored, as successful outcomes could lead to substantial shifts in INOVIO’s market dynamics.
INOVIO's strategic developments, including the potential market introduction of INO-3107 and the Phase 3 trial of INO-3112, position the company in a competitive stance within the biotech sector. The market research conducted indicates a strong preference among both patients and healthcare providers for non-surgical treatment options, which could facilitate market adoption of INO-3107 if approved. The anticipated reduction in surgical interventions by 81.3% (26/32 patients) is a compelling statistic that highlights the treatment's potential efficacy and marketability.
The company's efforts to build an infrastructure for commercial launch align with industry best practices, ensuring readiness to meet market demand quickly. The focus on distribution, supply chain and payer support reflects a comprehensive go-to-market strategy that could mitigate initial launch challenges.
For investors, the intersection of these clinical milestones and strategic market preparations suggests a promising outlook. The ability of INOVIO to effectively communicate and execute these strategies will be critical in realizing the potential market benefits.
- BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP)
- Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
- Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC) based on FDA feedback
- Balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in April 2024
- Cash runway projected into third quarter of 2025
"In the first quarter of 2024, we continued to deliver on our priorities for the year. Of utmost importance, we remain on track to submit our BLA in the second half of 2024 under the accelerated approval pathway for INO-3107 as a treatment for RRP and are working to initiate our confirmatory trial as soon as possible based on feedback from the FDA on the trial's design. We are energized by the opportunity to potentially deliver the first FDA-approved therapy for this devastating disease and continue to work expeditiously to be prepared to serve RRP patients and the physicians caring for them. If approved, INO-3107 would also be the first DNA medicine on the market in
Recent Business Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
- INOVIO remains on target to submit its BLA seeking accelerated approval for INO-3107 in the second half of 2024. INOVIO is preparing trial sites for recruitment based on recent feedback from the FDA that they had no additional comments on INOVIO's proposed design for the confirmatory trial. The trial is being strategically designed to focus on evaluating clinical benefit in reducing surgical intervention to control RRP disease for the majority of RRP patients. Repeat surgical interventions is the current standard of care for RRP. INOVIO's market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords.
- The proposed confirmatory trial will be randomized and placebo-controlled, involving approximately 100 patients with a history of ≥2 surgeries per year, with a treatment option for the placebo arm at trial end. This trial design is intended to target a broader spectrum of RRP disease than other candidates currently in development. If INO-3107 receives full approval from the FDA, INOVIO believes the design of the confirmatory trial could also support expansion into global markets based on feedback received to date from European regulators.
- Immunological data highlighting INO-3107's mechanism of action are expected to be submitted to peer-reviewed publications and key conferences in the second half of 2024.
- INOVIO continues preparations to be ready to launch commercially in 2025, should INO-3107 be approved. Efforts are focused on building the infrastructure needed to deliver the product to patients as quickly and easily as possible, from distribution and supply efforts to payer and healthcare provider support. INOVIO believes that INO-3107, if approved, has the potential to be the preferred treatment of choice for all patients with RRP, as well as healthcare professionals and payers based on results from completed clinical trials and the competitive strengths of the DNA medicine platform:
- Reduction in surgeries:
81.3% (26/32) of patients had a decrease in surgical interventions in the year after INO-3107 administration compared to the year prior to treatment, including28.1% (9/32) that required no surgical interventions during or after the dosing window. INOVIO's Phase 1/2 trial was designed to show the potential of INO-3107 to reduce surgical intervention in the year following the first dose compared to the year prior. Relative to other Phase 1/2 clinical trials, INOVIO's protocol required that all surgeries conducted during the dosing window (a 54-day period during which four doses were administered) be counted in the overall results. The protocol for INOVIO's trial also did not include prescribed laryngoscopy and surgery at weeks 6 and 12 to maintain minimal residual disease during the treatment window. INOVIO believes that these contrasts with other clinical trial designs are important and could offer competitive advantages for INO-3107 should it be approved. - Mechanism of action: INO-3107 generated antigen specific T cells with lytic potential targeting both HPV-6 and HPV-11.
- Immunology: Administration of INO-3107 induced active immune responses in the airway tissues of those patients who showed clinical response, including the production of cytokines and chemokines, known to be critical mediators of inflammatory responses, and increased activity of dendritic cells, macrophages and T cells. Additional analysis of T cell genes in airway tissues revealed an increase in CD4 and CD8 T cell gene signatures after treatment with INO-3107.
- Benefits of DNA plasmids plus electroporation: INOVIO's proprietary CELLECTRA® devices are designed to optimally deliver DNA medicines within the body's cells without requiring chemical adjuvants or lipid nanoparticles, and without the risk of pre-existing or anti-vector responses historically seen with viral vector platforms. In late-stage clinical trials involving approximately 5,600 doses administered to approximately 1,600 patients, intramuscular delivery has been well tolerated by patients and observed to be easy to use by healthcare providers. Based on historical data from other programs involving redosing, INOVIO believes it will be able to effectively re-dose INO-3107 if required to maintain or enhance immune responses.
- Reduction in surgeries:
INO-3112 – Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- The FDA provided feedback on the proposed Phase 3 trial design to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with locoregionally advanced, high-risk, HPV-16/-18 positive throat cancer.
- INOVIO will discuss the proposed trial design with European regulatory authorities, as INOVIO plans to conduct the trial in both
Europe andNorth America . - The combination of INO-3112 with LOQTORZI has the potential to address a substantial unmet need in patients with HPV-16 and -18 related high-risk throat cancer. The proposed multi-center Phase 3 trial will investigate whether LOQTORZI can help boost the tumor-infiltrating abilities of the antigen-specific T cells generated by INO-3112.
- INO-3112 is a DNA medicine candidate containing a DNA plasmid encoding HPV-16/-18 E6 and E7 antigens combined with another DNA plasmid encoding IL-12 as an immune activator.
- LOQTORZI is an FDA-approved PD-1 inhibitor approved for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma.
General Corporate
- Strengthened balance sheet with an offering of common stock and pre-funded warrants in April 2024; net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses, were approximately
$33.2 million
First Quarter 2024 Financial Results
- Cash, Cash Equivalents and Short-term Investments: As of March 31, 2024, cash, cash equivalents and short-term investments were
$105.6 million $145.3 million - Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2024, were
$20.9 million $30.2 million - General and Administrative (G&A) Expenses: G&A expenses were
$10.6 million $13.9 million - Total Operating Expenses: Total operating expenses were
$31.5 million $44.1 million - Reverse Stock Split: INOVIO effected a reverse stock split of its outstanding shares of common stock on January 24, 2024, as a result of which every twelve shares of its common stock issued and outstanding were combined into one share of common stock. Any fractional post-split shares as a result of the reverse split were eliminated and redeemed in cash. Outstanding share amounts and per share amounts included in this press release have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.
- Net Loss: INOVIO's net loss for the three months ended March 31, 2024 was
$30.5 million $1.31 $40.6 million $1.89 - Shares Outstanding: As of March 31, 2024, INOVIO had 23.4 million common shares outstanding and 25.1 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units and convertible preferred stock.
INOVIO's balance sheet and statement of operations are provided below. Additional information is included in INOVIO's quarterly report on Form 10-Q for the quarter ended March 31, 2024, which can be accessed at: http://ir.inovio.com/financials/default.aspx.
Cash Guidance
INOVIO estimates its cash runway, including the net proceeds of the April 2024 underwritten registered direct offering, to extend into the third quarter of 2025. This projection includes an operational net cash burn estimate of approximately
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, the planned submission of a BLA in the second half of 2024, plans for discussions with regulatory authorities, the planned commercial launch of INO-3107 if regulatory approval is obtained, and expectations with respect to our cash resources through the third quarter of 2025 and expected cash burn for the second quarter of 2024. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Inovio Pharmaceuticals, Inc. | |||
March 31, | December 31, | ||
(Unaudited) | |||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | |||
Short-term investments | 86,013,044 | 130,982,913 | |
Accounts receivable from affiliated entities | 2,551,082 | 2,405,228 | |
Prepaid expenses and other current assets | 3,517,081 | 5,393,665 | |
Prepaid expenses and other current assets from affiliated entities | — | 20,432 | |
Total current assets | 111,683,036 | 153,113,100 | |
Fixed assets, net | 5,015,067 | 4,960,986 | |
Investment in affiliated entity | 2,654,269 | 2,780,287 | |
Operating lease right-of-use assets | 9,156,478 | 9,491,735 | |
Other assets | 605,315 | 605,315 | |
Total assets | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable and accrued expenses | |||
Accounts payable and accrued expenses due to affiliated entity | 1,525,079 | 1,070,519 | |
Accrued clinical trial expenses | 3,022,486 | 2,365,382 | |
Operating lease liability | 2,155,540 | 2,406,522 | |
Grant funding liability | — | 87,489 | |
Grant funding liability from affiliated entity | 21,918 | 21,918 | |
Convertible senior notes | — | 16,770,654 | |
Total current liabilities | 23,400,945 | 42,570,228 | |
Operating lease liability, net of current portion | 11,271,257 | 11,032,066 | |
Total liabilities | 34,672,202 | 53,602,294 | |
Stockholders' equity: | |||
Preferred stock | — | — | |
Common stock | 23,370 | 22,792 | |
Additional paid-in capital | 1,748,529,814 | 1,740,954,074 | |
Accumulated deficit | (1,653,435,007) | (1,622,965,136) | |
Accumulated other comprehensive loss | (676,214) | (662,601) | |
Total Inovio Pharmaceuticals, Inc. stockholders' equity | 94,441,963 | 117,349,129 | |
Total liabilities and stockholders' equity | |||
Inovio Pharmaceuticals, Inc. | |||
Three Months Ended March 31, | |||
2024 | 2023 | ||
Revenue from collaborative arrangements and other contracts | $— | ||
Operating expenses: | |||
Research and development | 20,913,790 | 30,176,511 | |
General and administrative | 10,571,179 | 13,890,610 | |
Total operating expenses | 31,484,969 | 44,067,121 | |
Loss from operations | (31,484,969) | (43,952,178) | |
Other income (expense): | |||
Interest income | 1,500,290 | 2,207,171 | |
Interest expense | (177,833) | (313,488) | |
(Loss) gain on investment in affiliated entity | (126,018) | 616,639 | |
Net unrealized gain on available-for-sale equity securities | 500,877 | 3,218,215 | |
Other expense, net | (682,218) | (2,425,676) | |
Net loss | |||
Net loss per share | |||
Basic and diluted (1) | |||
Weighted average number of common shares outstanding | |||
Basic and diluted (1) | 23,291,512 | 21,536,476 | |
(1) | Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-first-quarter-2024-financial-results-and-recent-business-highlights-302143923.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When will INOVIO submit the BLA for INO-3107?
What is the potential market impact of INO-3107?
What is the status of the Phase 3 trial for INO-3112?
How has INOVIO's cash position changed?
What was the impact of the recent stock offering?
How did INOVIO's expenses change in Q1 2024?
What was INOVIO's net loss for Q1 2024?
